The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

Exposure to wildfire smoke may increase lung cancer patients' risk of dying from their disease, particularly among ...

A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from ...

MK-1084, Merck’s investigational KRAS G12C inhibitor, showed a manageable safety profile along with antitumor activity in the ...

A molecular test identified patients with high-risk early lung cancer who significantly benefitted from adjuvant chemotherapy ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

The FDA has accepted and granted priority review to an NDA for sevabertinib in previously treated HER2+ non-small cell lung ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

Stage 3 lung cancer is considered locally advanced with spread in the region near the site. Survival rates for stage 3 non-small cell lung cancer (NSCLC) range from as high as 36% to as low as 13% ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

A phase 2 trial found that adding bevacizumab to alectinib significantly delayed disease progression, protected against brain ...